In line with these findings, a study involving renal cell carcinoma patients receiving PD-1 pathway blockade monotherapy or combination therapy with CTLA-4 blockade showed that tumors with loss of function mutations in Pbrm1 correlated with clinical benefits from the treatment (74). This evidence concerns the gene PDCD1 and hereditary clear cell renal cell carcinoma.